134 related articles for article (PubMed ID: 22064092)
1. Ovarian thecoma mimicking carcinoma on F-18 FDG PET in a postmenopausal woman with elevated CA-125.
Su HM; Hu C; Tsay DG; Peng NJ
Clin Nucl Med; 2011 Dec; 36(12):1133-4. PubMed ID: 22064092
[No Abstract] [Full Text] [Related]
2. FDG-PET-positive ovarian thecoma with GLUT5 expression: Five cases.
Bono Y; Mizumoto Y; Nakamura M; Iwadare J; Obata T; Fujiwara H
J Obstet Gynaecol Res; 2017 Mar; 43(3):599-603. PubMed ID: 27987341
[TBL] [Abstract][Full Text] [Related]
3. Early detection of recurrent ovarian cancer in patients with low-level increases in serum CA-125 levels by 2-[F-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography.
Peng NJ; Liou WS; Liu RS; Hu C; Tsay DG; Liu CB
Cancer Biother Radiopharm; 2011 Apr; 26(2):175-81. PubMed ID: 21510748
[TBL] [Abstract][Full Text] [Related]
4. Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125.
Rubini G; Altini C; Notaristefano A; Merenda N; Rubini D; Ianora AA; Asabella AN
Rev Esp Med Nucl Imagen Mol; 2014; 33(1):22-7. PubMed ID: 23948509
[TBL] [Abstract][Full Text] [Related]
5. [18F-FDG PET/CT in patients, treated for ovarian cancer, with elevated CA 125 levels but no evidence of recurrence on conventional imaging].
Bochev P; Bocheva Y; Klisarova A; Ivanov S; Dancheva J; Chaushev B
Akush Ginekol (Sofiia); 2012; 51(1):18-27. PubMed ID: 22639775
[No Abstract] [Full Text] [Related]
6. [Peritoneal carcinomatosis from ovarian cancer: role of 18F-FDG-PET/CT and CA125].
Rubini G; Altini C; Notaristefano A; Merenda N; Rubini D; Stabile Ianora AA; Giganti M; Niccoli Asabella A
Recenti Prog Med; 2012 Nov; 103(11):510-4. PubMed ID: 23096741
[TBL] [Abstract][Full Text] [Related]
7. Ovarian thecoma-fibroma groups: clinical and sonographic features with pathological comparison.
Chen H; Liu Y; Shen LF; Jiang MJ; Yang ZF; Fang GP
J Ovarian Res; 2016 Nov; 9(1):81. PubMed ID: 27876070
[TBL] [Abstract][Full Text] [Related]
8. [Comparision of sonographic findings and pathological features in ovarian thecoma].
Chang Q; Hao YZ; Wu N; Zhu Q; Zhang X; Li M
Zhonghua Zhong Liu Za Zhi; 2008 Jun; 30(6):473-5. PubMed ID: 19024527
[TBL] [Abstract][Full Text] [Related]
9. Transvaginal color Doppler sonography and CA-125 elevation in a patient with ovarian thecoma and ascites.
Williams LL; Fleischer AC; Jones HW
Gynecol Oncol; 1992 Jul; 46(1):115-8. PubMed ID: 1321779
[TBL] [Abstract][Full Text] [Related]
10. Androgenetic alopecia in a postmenopausal woman as a result of ovarian hyperthecosis.
Kim Y; Marjoniemi VM; Diamond T; Lim A; Davis G; Murrell D
Australas J Dermatol; 2003 Feb; 44(1):62-6. PubMed ID: 12581085
[TBL] [Abstract][Full Text] [Related]
11. Unusual Case of Postmenopausal Diffuse Endometriosis Mimicking Metastastic Ovarian Malignancy.
Agarwal Sharma R; Lee EY; Vardhanabhuti V; Khong PL; Ngu SF
Clin Nucl Med; 2016 Feb; 41(2):e120-2. PubMed ID: 26462045
[TBL] [Abstract][Full Text] [Related]
12. Ovarian thecoma with ascites and high serum levels of CA125.
Takemori M; Nishimura R; Hasegawa K
Arch Gynecol Obstet; 2000 Jul; 264(1):42-4. PubMed ID: 10985621
[TBL] [Abstract][Full Text] [Related]
13. The role of FDG-PET/CT in ovarian cancer patients with high tumor markers or suspicious lesion on contrast-enhanced CT in evaluation of recurrence and/or in determination of intraabdominal metastases.
Sari O; Kaya B; Kara PO; Gedik GK; Celik C; Ozbek O; Serdengecti M
Rev Esp Med Nucl Imagen Mol; 2012; 31(1):3-8. PubMed ID: 21549452
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia is important in F‑18 FDG accumulation in thecoma‑fibroma tumors on F‑18 FDG PET/CT scans.
Seino H; Ono S; Miura H; Morohashi S; Wu Y; Tsushima F; Takai Y; Kijima H
Mol Med Rep; 2016 May; 13(5):3821-7. PubMed ID: 27035330
[TBL] [Abstract][Full Text] [Related]
15. Role of FDG PET-CT in asymptomatic epithelial ovarian cancer with rising serum CA-125: a pilot study.
Ghosh J; Thulkar S; Kumar R; Malhotra A; Kumar A; Kumar L
Natl Med J India; 2013; 26(6):327-31. PubMed ID: 25073988
[TBL] [Abstract][Full Text] [Related]
16. FDG PET/CT of a benign ovarian Brenner tumor.
Toriihara A; Taniguchi Y; Negi M; Kubota K; Makino T; Shibuya H
Clin Imaging; 2012; 36(5):650-3. PubMed ID: 22920385
[TBL] [Abstract][Full Text] [Related]
17. Whole-body PET with FDG is useful for following up an ovarian cancer patient with only rising CA-125 levels within the normal range.
Kurokawa T; Yoshida Y; Kawahara K; Tsuchida T; Fujibayashi Y; Yonekura Y; Kotsuji F
Ann Nucl Med; 2002 Nov; 16(7):491-3. PubMed ID: 12508842
[TBL] [Abstract][Full Text] [Related]
18. [Metabolic imaging with positron-emission tomography in the advanced-stage ovarian cancers].
Grahek D; Hassan-Sebbag N
Bull Cancer; 2009 Dec; 96(12):1163-71. PubMed ID: 19948451
[TBL] [Abstract][Full Text] [Related]
19. Whole body positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer.
Yen RF; Sun SS; Shen YY; Changlai SP; Kao A
Anticancer Res; 2001; 21(5):3691-4. PubMed ID: 11848544
[TBL] [Abstract][Full Text] [Related]
20. Dual-phase F-18 FDG PET/CT scanning in the suspicion of relapse of ovarian neoplasia.
Penna D; Varetto T; Deandreis D; Castellano G; Bisi G
Clin Nucl Med; 2009 Feb; 34(2):111-3. PubMed ID: 19352268
[No Abstract] [Full Text] [Related]
[Next] [New Search]
